Histogen’s growth factor technology will be marketed as part of Allergan's skin care line within its recently acquired Regenica® Advanced Rejuvenation System.
The Regenica line is based on multipotent CCM Complex (Cell Conditioned Media) which comprises active growth factors and proteins.
“Histogen has developed a next-generation regenerative cell technology, harnessing the power of growth factors and stem-cell signaling molecules for skin rejuvenation that complements Allergan’s flagship growth factor technology - TNS,” says Rahul Mehta, Ph.D. Vice President, Research & Development at SkinMedica, an Allergan Company, in a news release. “In addition to the Regenica product line, we are looking forward to collaborating with Histogen and leveraging their science to further bolster SkinMedica’s commitment to evidence-based skincare.”
First created at Histogen as a three-product line for anti-aging and post-resurfacing, Regenica was licensed by Suneva Medical in 2012 and has grown to the current Advanced Rejuvenation System of six products sold through medical aesthetic professionals throughout the world. The acquisition of the product line by Allergan now expands the reach of the technology.
“Allergan's world-class medical aesthetics portfolio, global footprint, history and commitment to developing innovative aesthetic products makes them ideally suited to realize the maximum potential of the Regenica growth factor technology for continued innovation in skincare,” says Dr. Gail Naughton, Histogen founder and inventor of its core technology.Next Story